Drug profile · INN
estropipate
ESTROPIPATE
estropipate (ESTROPIPATE) is a estrogen receptor alpha agonist. Associated with Teva Pharma GmbH. Route of administration: vaginal. Current US regulatory status: approved.
Drug details — estropipate
- US status
- approved
- Class
- —
- Route
- VAGINAL
- Patents
- 20
- Programs
- 152
- Data quality
- 0.89
Quick answer
estropipate (ESTROPIPATE) is a estrogen receptor alpha agonist. Associated with Teva Pharma GmbH. Route of administration: vaginal. Current US regulatory status: approved.
Key facts
Mechanism of action
Estrogen receptor alpha agonist
Primary target: Estrogen receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12410398
Methods of human retinal progenitor cell isolation and culture
granted -
US 12398193
Targeted replacement of endogenous T cell receptors
granted -
US 12397034
Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons
granted -
US 12390427
Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
granted -
US 12384753
17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
granted -
US 12370181
Regimens of estrogen receptor antagonists
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12370229
Methods of treating bladder cancer
granted -
US 12364745
Immunogenicity of a CpG-adjuvanted recombinant plague vaccine
granted -
US 12365653
Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
granted -
US 12365875
Methods for generating skeletal muscle progenitor cells
granted -
US 12357617
Discovery of novel anti-infectives for gram negative pathogens
granted -
US 12350322
Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation
granted -
US 12343321
Method for ameliorating or avoiding the adverse effects of exogenous gonadotropins on reproductive performance
granted -
US 12336982
Compositions and methods of modulating short-chain dehydrogenase activity
granted -
US 12338439
Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
granted -
US 12312345
Fluoroalkyl-oxadiazoles and uses thereof
granted -
US 12311016
Biomarkers and immunogenic compositions for filarial parasites
granted -
US 12310992
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
granted -
US 12297243
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
granted
Frequently asked questions
What is estropipate?
estropipate (ESTROPIPATE) is a estrogen receptor alpha agonist. Associated with Teva Pharma GmbH. Route of administration: vaginal. Current US regulatory status: approved.
What is the brand name for estropipate?
ESTROPIPATE is a marketed brand name for estropipate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of estropipate?
estropipate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.